Compare MYSZ & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYSZ | RDHL |
|---|---|---|
| Founded | 1999 | 2009 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 3.9M |
| IPO Year | N/A | N/A |
| Metric | MYSZ | RDHL |
|---|---|---|
| Price | $0.87 | $1.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 343.5K | 69.6K |
| Earning Date | 11-14-2025 | 09-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $7,512,000.00 | ★ $9,550,000.00 |
| Revenue This Year | $29.71 | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 157.62 |
| 52 Week Low | $0.73 | $1.01 |
| 52 Week High | $9.40 | $7.44 |
| Indicator | MYSZ | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 38.58 | 48.81 |
| Support Level | $0.96 | $1.18 |
| Resistance Level | $0.96 | $1.26 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 2.83 | 73.87 |
My Size Inc is a USA-based technology company that focuses on the development of an application that assists the consumer to accurately take the measurements of his or her own body to fit clothing without the need to try them on using a smartphone. The purpose of the company's business is to simplify the process of clothing acquisition through the Internet and to significantly reduce the rate of returns of clothing which were acquired through the internet and which are returned to the stores because of ill-fitting. The company generates its revenue through selling products to customers and licensing cloud-enabled software subscriptions, associated software maintenance, and support.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.